Teladoc Q4 2023 revenue $660.5M, adj. EBITDA up 22% to $114.4M; guides FY2024 revenue $2.64-2.74B

Teladoc Health, Inc.

2023-FY EPS reported -$1.34 revenue$2,602,415,000

Q4 revenue $660.5M (+4% YoY); Full year revenue $2,602.4M (+8% YoY).
Q4 net loss $28.9M ($0.17/sh) vs $3.81B loss a year ago; FY net loss $220.4M ($1.34/sh).
Q4 adjusted EBITDA $114.4M (+22% YoY); FY adj. EBITDA $328.1M (+33% YoY); FY free cash flow $193.7M.
FY2024 guidance: revenue $2,635-2,735M, adj. EBITDA $350-390M, free cash flow $210-240M.
Efficiency program targets ~$43M net expense reduction in 2024; expects $85M annualized savings.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Teladoc Health, Inc. reported the full year ended December 31, 2023 results: revenue $2,602.4 million, net income $220.4 million, EPS $1.34 per share. Guidance initiated.

Period: the full year ended December 31, 2023
Revenue: $2,602.4 million
Net income: $220.4 million
EPS: $1.34 per share
Guidance: initiated
Result: reported results

Exact text from the filing

Teladoc Health Reports Fourth Quarter and Full Year 2023 Results • Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million • Fourth quarter 2023 net loss of $28.9 million, or $0.17 per share, and full year 2023 net loss of $220.4 million, or $1.34 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Teladoc Health, Inc. reported the fourth quarter of 2023 results: revenue $660.5 million, net income $28.9 million, EPS $0.17 per share. Guidance initiated.

Period: the fourth quarter of 2023
Revenue: $660.5 million
Net income: $28.9 million
EPS: $0.17 per share
Guidance: initiated
Result: reported results

Exact text from the filing

$ (84.60) 98 % Adjusted EBITDA (1) $ 114,443 $ 94,094 22 % $ 328,120 $ 246,513 33 % See note (1) in the Notes section that follows. 1 Fourth Quarter 2023 Revenue increased 4% to $660.5 million from $637.7 million in the fourth quarter of 2022. Access fees revenue grew 4% to $573.9 million and other revenue grew 3% to $86.6 million. U.S. revenue grew 2% to $564.8

View on SEC.gov

Browse all earnings releases →

Teladoc Health, Inc. filing history →

Source: SEC EDGAR

accession 0001477449-24-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.